Outlook Wealth Advisors LLC Purchases 15,088 Shares of Invesco Biotechnology & Genome ETF $PBE

Outlook Wealth Advisors LLC acquired a new stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 15,088 shares of the company’s stock, valued at approximately $1,468,000. Outlook Wealth Advisors LLC owned approximately 0.35% of Invesco Biotechnology & Genome ETF at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Royal Bank of Canada boosted its holdings in Invesco Biotechnology & Genome ETF by 25.9% during the 1st quarter. Royal Bank of Canada now owns 59,329 shares of the company’s stock valued at $4,698,000 after acquiring an additional 12,215 shares during the period. Cetera Investment Advisers increased its stake in Invesco Biotechnology & Genome ETF by 2.0% during the first quarter. Cetera Investment Advisers now owns 23,139 shares of the company’s stock worth $1,832,000 after purchasing an additional 464 shares during the period. YHB Investment Advisors Inc. acquired a new stake in shares of Invesco Biotechnology & Genome ETF during the third quarter worth about $2,169,000. Envestnet Asset Management Inc. lifted its position in shares of Invesco Biotechnology & Genome ETF by 4.2% during the second quarter. Envestnet Asset Management Inc. now owns 22,250 shares of the company’s stock worth $1,995,000 after purchasing an additional 888 shares in the last quarter. Finally, Penobscot Investment Management Company Inc. purchased a new position in shares of Invesco Biotechnology & Genome ETF in the third quarter valued at approximately $1,892,000.

Invesco Biotechnology & Genome ETF Stock Performance

NYSEARCA PBE opened at $102.50 on Friday. The firm has a 50 day simple moving average of $96.99 and a 200-day simple moving average of $87.26. Invesco Biotechnology & Genome ETF has a one year low of $73.16 and a one year high of $104.24. The firm has a market cap of $445.88 million, a price-to-earnings ratio of 20.44 and a beta of 0.70.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.